Tessa Romero
Stock Analyst at JP Morgan
(4.28)
# 373
Out of 5,245 analysts
86
Total ratings
49.25%
Success rate
19.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Overweight | $38 → $42 | $29.49 | +42.42% | 2 | May 18, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $77 → $80 | $54.17 | +47.68% | 5 | May 12, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $92 → $97 | $76.94 | +26.07% | 8 | May 12, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $31 → $36 | $28.14 | +27.93% | 9 | Apr 6, 2026 | |
| SEPN Septerna | Maintains: Overweight | $34 → $38 | $28.36 | +33.99% | 1 | Mar 24, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $34 → $45 | $32.70 | +37.61% | 12 | Mar 17, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $47 → $50 | $48.13 | +3.89% | 7 | Mar 16, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.10 | +61.14% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $17.37 | -7.89% | 8 | Jan 20, 2026 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.45 | +58.73% | 8 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $261 → $263 | $2.96 | +8,785.14% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.85 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $5.11 | +95.69% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $8.37 | +354.00% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.92 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $12.93 | +124.28% | 3 | Aug 13, 2024 |
Oculis Holding AG
May 18, 2026
Maintains: Overweight
Price Target: $38 → $42
Current: $29.49
Upside: +42.42%
Xenon Pharmaceuticals
May 12, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $54.17
Upside: +47.68%
Cytokinetics
May 12, 2026
Maintains: Overweight
Price Target: $92 → $97
Current: $76.94
Upside: +26.07%
Agios Pharmaceuticals
Apr 6, 2026
Maintains: Neutral
Price Target: $31 → $36
Current: $28.14
Upside: +27.93%
Septerna
Mar 24, 2026
Maintains: Overweight
Price Target: $34 → $38
Current: $28.36
Upside: +33.99%
Edgewise Therapeutics
Mar 17, 2026
Maintains: Overweight
Price Target: $34 → $45
Current: $32.70
Upside: +37.61%
Scholar Rock Holding
Mar 16, 2026
Maintains: Overweight
Price Target: $47 → $50
Current: $48.13
Upside: +3.89%
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $21.10
Upside: +61.14%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $17.37
Upside: -7.89%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.45
Upside: +58.73%
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $2.96
Upside: +8,785.14%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.85
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $5.11
Upside: +95.69%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $8.37
Upside: +354.00%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $7.92
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $12.93
Upside: +124.28%